SFM
VKTX icon

Signet Financial Management’s Viking Therapeutics VKTX Stock Holding History

Signet Financial Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,015
Closed -$53K – 814
2018
Q3 		$53K Buy
+3,015
New +$35.9K 0.01% 387

Other funds holding VKTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Signet Financial Management's VKTX Position: Q4 2018 in Review

Signet Financial Management sold out of Viking Therapeutics (VKTX) in Q4 2018, closing a stake of 3,015 shares — an estimated $53K sold.

Signet Financial Management first reported a position in VKTX in Q3 2018 and held it in 1 quarter. The position peaked at $53K in Q3 2018. 168 funds tracked by Wall St. Rank hold VKTX as of Q4 2018.

  • Signet Financial Management reported no remaining Viking Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Signet Financial Management sold 3,015 Viking Therapeutics shares in Q4 2018, an estimated $53K.
  • Signet Financial Management first reported a position in Viking Therapeutics in Q3 2018 and held it in 1 quarter.
  • Signet Financial Management's Viking Therapeutics position peaked at $53K in Q3 2018.
  • 168 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2018.

Based on Signet Financial Management's 13F filing for Q4 2018, filed 14 Feb 2019.